CStone Pharmaceuticals (HKG:2616) said a patent was published for its internally developed antibody-drug conjugate (ADC) CS5006 on October 10, according to a filing with the Hong Kong bourse.
CS5006 is a new type of cancer drug designed to target a protein called integrin β4 (ITGB4), which combines with another protein, integrin α6 (ITGA6), to form a pair called α6β4. Using advanced technology and AI, researchers found that ITGB4 is common in cancers like lung, colon, esophageal, and head and neck cancers. This discovery suggests that targeting ITGB4 may be an effective way to treat these cancers.
The pharmaceutical company's shares were down nearly 3% in recent trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。